share_log

Cassava Sciences | ARS: Annual Report to Security Holders

Cassava Sciences | ARS: Annual Report to Security Holders

Cassava Sciences | ARS:年度报告
美股sec公告 ·  03/22 09:02
Moomoo AI 已提取核心信息
Cassava Sciences, Inc., a clinical-stage biotechnology company, reported its financial results for the fiscal year ended December 31, 2023. The company, which focuses on the development of novel drugs and diagnostics for neurodegenerative diseases such as Alzheimer's, has not generated any revenue from product sales and reported a net loss of $97.2 million for the year. Cassava Sciences' lead therapeutic drug candidate, simufilam, is currently in Phase 3 clinical trials for the treatment of Alzheimer's disease dementia. The company also has an investigational diagnostic product candidate, SavaDx, aimed at detecting Alzheimer's disease from a blood sample. Cassava Sciences ended the year with $121.1 million in cash and cash equivalents and believes its existing funds will be sufficient to support operations for...Show More
Cassava Sciences, Inc., a clinical-stage biotechnology company, reported its financial results for the fiscal year ended December 31, 2023. The company, which focuses on the development of novel drugs and diagnostics for neurodegenerative diseases such as Alzheimer's, has not generated any revenue from product sales and reported a net loss of $97.2 million for the year. Cassava Sciences' lead therapeutic drug candidate, simufilam, is currently in Phase 3 clinical trials for the treatment of Alzheimer's disease dementia. The company also has an investigational diagnostic product candidate, SavaDx, aimed at detecting Alzheimer's disease from a blood sample. Cassava Sciences ended the year with $121.1 million in cash and cash equivalents and believes its existing funds will be sufficient to support operations for at least the next 12 months. The company's financial position was also bolstered by a registered direct offering in November 2022, which raised approximately $47.3 million in net proceeds. Cassava Sciences continues to invest in research and development, with expenses totaling $89.4 million in 2023, a 31% increase from the previous year. The company's stock has been volatile, with fluctuations influenced by the progress of its clinical trials and market conditions in the biotechnology sector.
处于临床阶段的生物技术公司木薯科学公司报告了截至2023年12月31日的财年财务业绩。该公司专注于开发用于阿尔茨海默氏症等神经退行性疾病的新药和诊断方法,但尚未从产品销售中产生任何收入,并报告该年度的净亏损为9,720万美元。Cassava Sciences的主要候选治疗药物simufilam目前正在进行治疗阿尔茨海默氏病痴呆的3期临床试验。该公司还有一种研究性候选诊断产品SavaDx,旨在从血液样本中检测阿尔茨海默氏病。Cassava Sciences在年底拥有1.211亿美元的现金和现金等价物,并认为其现有资金将足以支持至少未来12个月的运营。2022年11月的注册直接发行也提振了该公司的财务状况,该发行筹集了约4,730万美元的净收益。木薯科学继续投资于研发,2023年的支出总额为8,940万美元,比上年增长31%。该公司的股票一直波动不定,其波动受其临床试验进展和生物技术领域市场状况的影响。
处于临床阶段的生物技术公司木薯科学公司报告了截至2023年12月31日的财年财务业绩。该公司专注于开发用于阿尔茨海默氏症等神经退行性疾病的新药和诊断方法,但尚未从产品销售中产生任何收入,并报告该年度的净亏损为9,720万美元。Cassava Sciences的主要候选治疗药物simufilam目前正在进行治疗阿尔茨海默氏病痴呆的3期临床试验。该公司还有一种研究性候选诊断产品SavaDx,旨在从血液样本中检测阿尔茨海默氏病。Cassava Sciences在年底拥有1.211亿美元的现金和现金等价物,并认为其现有资金将足以支持至少未来12个月的运营。2022年11月的注册直接发行也提振了该公司的财务状况,该发行筹集了约4,730万美元的净收益。木薯科学继续投资于研发,2023年的支出总额为8,940万美元,比上年增长31%。该公司的股票一直波动不定,其波动受其临床试验进展和生物技术领域市场状况的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息